04/03/2026
We’re proud to announce that TFS HealthScience has been selected as the clinical partner for two pivotal Phase 2/3 global studies in Neovascular Age-Related Macular Degeneration (nAMD). Spanning 23 countries across North America, Europe, South America, and Australia, these studies will involve more than 300 clinical sites and over 1,900 patients worldwide.
This accomplishment continues to demonstrate our comprehensive capabilities and collaborative strength in driving innovation across all our therapeutic areas, in the expansion of current markets and global footprint. Showcasing our growing legacy in ophthalmology, our team has supported programs that have helped advance meaningful innovation in retinal disease, including contributing to the approval of one of the first treatments for Geographic Atrophy. Our approach remains consistent: strong scientific partnership, operational excellence, and a clear focus on patients. We’re grateful for the opportunity to support these important studies and to continue advancing research in nAMD together with our partners.